TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Additionally, as TransMedics plans to enter the dynamic cold perfusion market in the second half of 2025, it may face more direct competition from established players like XVIVO. This increased ...

Additionally, as TransMedics plans to enter the dynamic cold perfusion market in the second half of 2025, it may face more direct competition from established players like XVIVO. This increased ...

The crucial limitation in paediatric cardiac donation in DCD has been technological, as the currently approved ex situ mechanical perfusion device (TransMedics OCS Heart ... child DCD heart recovery.

BURLINGAME, CA, UNITED STATES, January 14, 2025 /EINPresswire / -- The Perfusion System Market Report is the result of extensive research and analysis conducted by our team of experienced market ...

paints a grim picture of TransMedics' business practices. The report's allegations center on the company's warm perfusion technology platform, known as the Organ Care System (OCS), and its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

TransMedics (NASDAQ ... Transporters use oxygenated perfusion at low temperatures, however, do not fully mimic physiological conditions. The TransMedics Organ Care System, OCS is a revolutionary ...